Objective: To study the immunomodulatory effect of teriflunomide on innate and adaptive immune cell populations through a pilot, open-label, observational study in a cohort of patients with relapsing-remitting MS.
The main mechanism of action of teriflunomide, a drug approved for treatment of relapsingremitting MS (RR-MS), relies on the inhibition of dihydroorotate dehydrogenase, which catalyzes de novo biosynthesis of pyrimidines. Cells with high proliferative rates, such as activated lymphocytes, are therefore affected by teriflunomide. 1 Accordingly, treatment with teriflunomide decreases proliferation of T and B lymphocytes. 2 Clinical trials (teriflunomide multiple sclerosis oral and teriflunomide oral in people with relapsing multiple sclerosis) 3 have shown that teriflunomide treatment is associated with an early 15% mean decrease in leukocyte counts. However, the effect of teriflunomide on different immune cell subpopulations has not been properly addressed so far. Therefore, we have investigated how teriflunomide treatment affects immune cell populations in MS.
METHODS Flow cytometry analysis. Mononuclear cells were isolated from the peripheral blood by Ficoll gradient centrifugation (Lympholyte-H, Cedarlane), and flow cytometry analysis, using the BD LSRFortessa flow cytometer and FACSDiva 7 Software, was performed in 4 tubes using the following conjugated antibodies (Becton Dickinson, Franklin Lakes, NJ): anti-CD3 (V500), anti-CD4 (allophycocyanin [APC]-H7), anti-CD8 (PercCP-Cy5.5), anti-CD28 (phycoerythrin [PE], anti-CD25 (PE.Cy7), anti-CD127 (BV421), anti-CD45RA (APC), anti-CCR6 (APC), anti-CD161 (B421), anti-CCR4 (PE.Cy7), and anti-CXCR3 (PE) for effector (Teff) and regulatory T (Treg) cells; anti-CD19 (PE.Cy7), anti-CD38 (APC), and anti-CD24 (PE) for B cells; and anti-CD3 (V500), anti-CD16 (PerCp-Cy5.5), and anti-CD56 (BV421) for natural killer (NK) cells.
Flow-Count Fluorospheres (Beckman Coulter, Galway, Ireland) were used to obtain absolute cell counts.
MS patient cohort.
The longitudinal, open-label, observational study was performed on a cohort of 10 patients with RR-MS; of these, 3 were analyzed before treatment (T0) and after 3 months (T3), and 7 at T0 and after 12 months (T12) of treatment. The 3 patients followed for 3 months (2 men and 1 woman) had a mean age of 43.6 6 1.5 years, a mean Expanded Disability Status Scale (EDSS) score of 3.0 6 1.5 throughout treatment, and a mean disease duration of 15.3 6 10.5 years. One patient had been treated with mitoxantrone for 6 years previously. The 7 patients followed for 12 months were all women with a mean age of 54.8 6 8.9 years; the mean EDSS score was 3.0 6 1.5 and 3.1 6 1.7 before and after 12 months of treatment, respectively, and a mean disease duration of 13.4 6 4.8 years. One patient had been treated with cyclophosphamide and mitoxantrone 7 years previously. Other previous treatments included interferonb-1a, interferonb-1b, natalizumab, and dimethyl fumarate. Patients did not experience relapses during treatment.
Patients were enrolled according to the following criteria: age 18 years and older, with a diagnosis of RR-MS (Poser or McDonald criteria) and an EDSS score of 0-6.5, and able to provide written informed consent.
Ethics approval. Statistical analyses. Statistical analyses were performed using Graph-Pad Prism v.6.00 (GraphPad Software, San Diego, CA). Statistical significance was evaluated using the paired Student t test (Wilcoxon matched-pairs signedrank test). p Values #0.05 were considered statistically significant. RESULTS A preliminary assessment by flow cytometry of the effect of teriflunomide on broad immune cell subsets (CD3 1 T cells, CD19
1 B cells, and CD56
1 NK cells) in 3 patients after a three-month treatment indicated that CD19
1 B-cell percentage and numbers decreased in all 3 patients (figure 1A), while no apparent effect was observed in the other cell populations (data not shown). To further define the effect of teriflunomide, we evaluated its effect on cell number and proportion of relevant immune cell subsets after a 12-month treatment in 7 different patients. As expected, the overall lymphocyte counts in all treated patients were slightly decreased (by around 10%; data not shown).
B cells decrease in patients with MS during teriflunomide treatment. A significant reduction in cell number and percentage of B cells overall was confirmed in patients treated for 12 months ( figure 1B) . While the proportions of the different B-cell subpopulations remained stable ( figure 1C upper panel) , B mature and B regulatory cell numbers were significantly decreased, and B memory cells also T effector and regulatory cell numbers show a slight trend in reduction after 12 months of teriflunomide treatment
Effector T-cell populations were assessed as Th1 (CD3 Figure 3 shows that percentage and numbers of total NK cells remained stable after 12 months of treatment (figure 3, A and C), and there was no difference in the proportion and absolute counts of CD56 bright and CD56 dim NK cells (Figure 3, B and D) . DISCUSSION 
MS is an inflammatory autoimmune disease involving several types of immune cells with effector and regulatory functions including T and B lymphocytes. While autoreactive CD4
1 Teff cells are believed to drive autoimmune diseases when they escape central tolerance, several mechanisms have evolved to regulate their function in the periphery and prevent autoimmunity. Different Treg-cell subsets have been characterized as being able to suppress lymphocyte effector functions either directly or by acting on antigen-presenting cells, therefore preventing the development of autoimmunity. In MS, Treg suppression has been reported to be dysfunctional. The role of Th1 interferon gamma (IFNg)-secreting cells is well known as a major protagonist in demyelinating damage in MS 4 ; more recently, other Teff-cell subpopulations have been discovered to have a major role in the inflammatory process of MS: Th17 and Th1/17 lymphocytes secreting IFNg and/ or interleukin-17. In particular, Th1/17 cells are increased in patients with MS compared with healthy donors during active phases of disease. 5 Our data show that the numbers of circulating Teff and Treg cells are slightly, albeit not significantly, decreased by teriflunomide treatment. As teriflunomide affects predominantly cells that are highly proliferative, this suggests that, in our cohort of patients who did not suffer any relapse during the period of observation, the rate of proliferation of these cells is likely low.
B lymphocytes are emerging as key player in the pathogenesis of MS. Three B-cell subsets have been described: effector, regulatory, and memory cells characterized by different roles depending on the production of antibody and of different cytokine types. Aberrant profiles of both types of cytokine responses have been observed in B cells from patients with MS. 6 Our study shows that teriflunomide significantly decreases cell numbers of effector B-cell subsets, confirming the importance of targeting B cells to obtain clinical and radiologic stabilization of disease, as shown with B-cell-specific treatments such as rituximab 7 and ocrelizumab. 8 The effect of teriflunomide on mature B cells may be of clinical importance in view of the observed recirculation of B cells between peripheral tissues and the CNS, with a possible pathogenetic effect. However, teriflunomide also decreases the Breg-cell subset, as its effect on lymphocytes is not specific toward a single cell population, but rather targets proliferating cells. It is as yet unknown what are the roles of Breg cells in MS and the clinical relevance of changes induced by treatments on this cell population. However, it should be noted that efficient specific B-cell-depleting treatments such as rituximab and ocrelizumab, would also affect the Breg-cell population. In this context, beyond its current utilization as first-line therapy in MS subjects, teriflunomide could be also considered as maintenance treatment after induction therapy.
Our data show that teriflunomide treatment influences immune cell subsets involved in the pathogenesis of MS, more specifically B cells and, to a lower extent, T cells. However, further studies with larger cohorts and targeting cell functionality are necessary to clarify the basis of its efficacy in MS.
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